Skip to Main Content

A few months ago, a federal court judge dismissed all claims against more than a dozen generic manufacturers over allegations that their versions of the Zantac heartburn pill may contain a carcinogen. Now, those companies are seeking to recover potentially significant costs from approximately 1,000 people who filed the lawsuits alleging they were harmed by the pills.

In a recently filed motion, the generic companies indicated they plan to submit a request to recover various costs — such as copies of transcripts — that were incurred since the sprawling litigation began in 2019. Although such costs are generally modest, the numerous depositions and court hearings involving multiple companies suggest such expenses may have been sizable, according to experts.


The generic companies, which are also seeking to recover the costs for a court-appointed special master who manages complex litigation, have already asked the court to seal their upcoming requests. An attorney for the generic companies — including Apotex, Aurobindo, Dr. Reddy’s Laboratories, Heritage Pharmaceuticals, Lannett, Sandoz, and Teva Pharmaceuticals (TEVA) — declined to comment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.